Exploration of Targeted Anti-tumor Therapy

Variable	Studies (n)	Patients (n)	Telomere length	OR (95% CI)	P-value	Heterogeneity	Model
Tumor grade (3 vs. 1–2)	2	683	165 vs. 297	78 vs. 143	1.29 (0.90–1.85)	0.17	0	0.86	Fixed
Tumor stage (III–IV vs. I–II)	3	905	32 vs. 603	21 vs. 249	1.18 (0.65–2.16)	0.58	0	0.89	Fixed
Menopausal status (premenopausal vs. postmenopausal)	2	1,516	314 vs. 614	170 vs. 418	1.34 (1.06–1.70)	0.01^*	20.84	0.26	Fixed
Lymph node metastasis (positive vs. negative)	2	389	101 vs. 102	95 vs. 91	1.45 (0.34–6.26)	0.62	83.33	0.01	Random
HER2 (positive vs. negative)	2	1,550	514 vs. 436	379 vs. 221	0.92 (0.73-1.15)	0.44	0	0.51	Fixed
ER (positive vs. negative)	3	1,522	736 vs. 198	431 vs. 157	1.12 (0.86–1.44)	0.40	0	0.75	Fixed
PR (positive vs. negative)	3	1,521	633 vs. 302	406 vs. 180	0.93 (0.73–1.19)	0.58	42.81	0.58	Fixed

Variable

Studies (n)

Patients (n)

Telomere length

OR (95% CI)

P-value

Heterogeneity

Model

Short

Long

I² (%)

Tumor grade (3 vs. 1–2)

683

165 vs. 297

78 vs. 143

1.29 (0.90–1.85)

0.17

0.86

Fixed

Tumor stage (III–IV vs. I–II)

905

32 vs. 603

21 vs. 249

1.18 (0.65–2.16)

0.58

0.89

Fixed

Menopausal status (premenopausal vs. postmenopausal)

1,516

314 vs. 614

170 vs. 418

1.34 (1.06–1.70)

0.01^*

20.84

0.26

Fixed

Lymph node metastasis (positive vs. negative)

389

101 vs. 102

95 vs. 91

1.45 (0.34–6.26)

0.62

83.33

0.01

Random

HER2 (positive vs. negative)

1,550

514 vs. 436

379 vs. 221

0.92 (0.73-1.15)

0.44

0.51

Fixed

ER (positive vs. negative)

1,522

736 vs. 198

431 vs. 157

1.12 (0.86–1.44)

0.40

0.75

Fixed

PR (positive vs. negative)

1,521

633 vs. 302

406 vs. 180

0.93 (0.73–1.19)

0.58

42.81

0.58

Fixed